PROCEPT Biorobotics Corp. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This filing is the Annual Report on Form 10-K for PROCEPT Biorobotics Corporation for the fiscal year ended December 31, 2025. PROCEPT is a surgical robotics company focused on urology, specifically treating benign prostatic hyperplasia (BPH) using its proprietary Aquablation therapy. The company markets two robotic systems: the AquaBeam Robotic System and the next-generation HYDROS Robotic System (FDA cleared in August 2024). As of December 31, 2025, the company had a global install base of 912 systems, with 718 located in the United States.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $308.1 million | $224.5 million |
| Gross Profit | $196.2 million | $137.1 million |
| Gross Margin | 64% | 61% |
| Net Loss | $(95.6) million | $(91.4) million |
| Operating Loss | $(103.9) million | $(96.6) million |
| Cash and Cash Equivalents | $286.5 million | $333.7 million |
| Long-Term Debt | $52.0 million | $52.0 million |
| Accumulated Deficit | $(641.6) million | $(546.0) million |
Revenue Breakdown (2025): System sales and rentals ($106.1 million), Handpieces and consumables ($181.4 million), and Service ($20.5 million). U.S. revenue accounted for 88% of total revenue.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 37% year-over-year, driven primarily by a 49% increase in handpiece and consumable sales ($60.0 million increase) and an 18% increase in system sales ($15.8 million increase).
- Margin Expansion: Gross margin improved from 61% to 64%, attributed to higher unit sales spreading fixed manufacturing overhead costs, partially offset by increased warranty costs.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 33% to $228.8 million due to expanded commercial infrastructure. Research and Development (R&D) expenses increased 14% to $71.3 million.
- Debt Restructuring: In August 2025, the company amended its loan agreement with Canadian Imperial Bank of Commerce (CIBC). The amendment modified repayment terms to require the entire principal amount to be due at maturity (October 2027) rather than monthly amortization. It also adjusted cash collateral requirements.
- Leadership Transition: The company announced a planned transition in the Chief Executive Officer role in July 2025, with Larry Wood assuming the role.
Guidance, Outlook, and Risks
Outlook and Strategy: Management expects to continue incurring operating losses for the foreseeable future. The company believes its current cash and anticipated revenue are sufficient to fund operations for at least the next 12 months. Strategic priorities include growing the install base, increasing system utilization, broadening private payor coverage, and investing in clinical research for prostate cancer indications (WATER IV PCa trial).
Key Risks and Contingencies:
- Profitability: The company has a history of significant net losses and an accumulated deficit of $641.6 million; there is no assurance it will achieve or sustain profitability.
- Reimbursement: Revenue is highly dependent on third-party coverage and reimbursement rates. Changes in Medicare or commercial payor policies could materially impact demand.
- Debt Covenants: The loan agreement contains restrictive covenants, including minimum cash reserve requirements and revenue growth targets if cash balances fall below $100 million. Failure to comply could trigger an event of default.
- Supply Chain: The company relies on single-source suppliers for critical components, creating vulnerability to supply shortages.
- Regulatory: Ongoing regulatory scrutiny and the need for future clearances for product modifications or new indications pose risks to commercialization.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $286.5 million cash balance against the projected burn rate and the impact of the amended debt covenants requiring specific cash reserves at CIBC.
- Reimbursement Stability: Monitor updates on Medicare and commercial payor coverage decisions, as these are critical drivers for hospital adoption and handpiece utilization.
- Debt Covenant Compliance: Review quarterly reports to ensure the company maintains the required minimum unrestricted cash or revenue growth targets to avoid default on the $52.0 million term loan.
- Leadership Transition: Assess the impact of the CEO transition on strategic execution and operational stability.
- Product Mix: Track the ratio of system sales to consumable sales to evaluate the maturity of the install base and recurring revenue potential.